Why Human and Mouse Whole Exome Sequencing?

Whole exome sequencing (WES) focuses on the coding regions (exons) of the genome, which represent just 1–2% of the human or mouse genome yet contain over 85% of known disease-related variants. By selectively sequencing only these high-value regions, WES provides a cost-effective alternative to whole genome sequencing (WGS) without sacrificing discovery power for most functional mutations.

Whether you're studying rare inherited disorders, tumour mutations, or developing disease models in mice, exome sequencing offers deep insight into protein-coding changes that drive phenotype and pathology.

Key Advantages of Exome Sequencing:

• Efficient and high-resolution: Pinpoints single-nucleotide variants (SNVs), insertions/deletions (InDels), and copy number variations (CNVs) across all protein-coding regions.
• Cost-effective alternative to WGS: Delivers actionable data at a fraction of the cost and data volume.
• Ideal for human disease and mouse model research: Enables comparative genomics, mutation screening, and translational insights across species.
• Flexible for research needs: Supports germline and somatic variant discovery, population studies, and targeted functional analysis.
• Enhanced variant annotation: Leverages comprehensive databases including RefSeq, ClinVar, CCDS, and GENCODE.

At N2 Jenomics Lab Pvt. Ltd. , we offer both Human/Mouse Whole Exome Sequencing and  Plant/Animal Whole Exome Sequencing, with customizable depth, platform, and analysis options to suit your specific research goals.

Our Human and Mouse Exome Sequencing Services

Human Exome Sequencing Service

Our Human Whole Exome Sequencing is based on GRCh38 and captures up to 99.9% of known protein-coding regions across RefSeq, MANE, CCDS, and ClinVar databases. Choose from standard or disease-focused Human Exome Panels:

• Core Panel: Optimized for high exonic coverage and efficient data yield.
• Inherited Disease Panel: Adds ClinVar pathogenic sites, mtDNA, and high-density CNV probe backbones.
• Cancer Panel: Includes 600+ tumour-associated genes, fusion regions, HLA loci, and MSI markers.

We support flexible sequencing depths (100X–200X) with options for FFPE, blood, or tissue samples.

Mouse Exome Sequencing Service

Our Mouse Whole Exome Sequencing uses a proprietary Mouse Exome Panel designed from the mm39 genome, covering over 38 Mb of CDS regions with high capture uniformity. This allows for efficient, low-input sequencing with excellent depth (100X+) using just 8 Gb of data.

• Use our mouse platform for:
• Phenotype-to-genotype studies
• Transgenic and knockout mouse validation
• Preclinical disease model analysis

Human and Mouse Exome Sequencing Panels at N2 Jenomics Lab Pvt. Ltd.

Technology Platforms for Exome Sequencing

At N2 Jenomics Lab Pvt. Ltd. , we provide comprehensive exome sequencing using both short-read and long-read platforms to meet diverse project requirements in disease research, drug discovery, and functional genomics.

Supported Platforms

• Illumina NovaSeq & NextSeq
  Industry-standard short-read sequencing for high-depth, high-throughput applications.
  Ideal for detecting single nucleotide variants (SNVs) and small insertions/deletions (InDels) across coding regions.
• MGI DNBSEQ
  A cost-effective alternative to Illumina, offering comparable accuracy and coverage uniformity.
  Suitable for mouse exome projects requiring scalability and rapid turnaround.
• Nanopore PromethION
  Long-read sequencing platform capable of capturing extended exons, fusion events, and complex structural variants.
  Useful for characterizing splicing isoforms, gene fusions, and hard-to-map GC-rich exons.
• PacBio Revio / Sequel IIe (HiFi reads)
  Enables high-fidelity long reads (HiFi) for precise exon-level phasing, CNV detection, and de novo assembly in targeted regions.
  Especially beneficial in capturing full-length transcripts and resolving repeats in human and mouse models.

Read Lengths and Coverage

Exome Capture Strategies

• Hybridization-based Capture
  Optimized probe sets designed to enrich coding sequences from human and mouse genomes.
  Custom panel options available upon request for focused disease gene sets or orthologous regions.
• Amplicon-Free Workflows
  For degraded or FFPE samples, we employ enzymatic fragmentation and low-input protocols to ensure robust performance.

Workflow

Data Analysis

Our bioinformatics pipeline delivers high-confidence variant calls and comprehensive interpretation for both human and mouse exomes. Each dataset is analysed using gold-standard algorithms to ensure reliable detection of clinically and functionally relevant variants.

What's Included in Our Exome Data Analysis:

• Quality control of raw sequencing reads (Phred score, adapter trimming, contamination filtering)
• Alignment to reference genome (GRCh38 for human, GRCm39 for mouse) using BWA-MEM
• Duplicate marking and base quality recalibration with GATK Best Practices
• Variant calling (SNVs and small InDels) using GATK HaplotypeCaller
• Functional annotation with Ensembl VEP and ClinVar/OMIM/gnomAD
• Rare variant filtering based on allele frequency thresholds
• Pathogenicity prediction using tools like SIFT, PolyPhen-2, MutationTaster
• CNV calling (for high-coverage samples) using CNVkit or XHMM
• Tumor samples (optional): MSI/TMB analysis and somatic mutation calling

Technical Process

Advanced Technical Process

Advantages of Our Exome Sequencing Services

Our exome sequencing services are optimized for precision, flexibility, and cross-species compatibility. Whether you're studying rare diseases, cancer, or functional genomics in mouse models, we deliver high-quality data—fast.

Dual-Species Expertise

Validated human and mouse exome panels covering >99% coding regions (RefSeq, MANE, CCDS).

Flexible Platforms

Illumina, MGI for short reads; Nanopore, PacBio for long reads and complex regions.

Customizable Targets

Add HLA, CNV scaffolds, mitochondrial genome, or disease-specific regions.

High Uniformity & Sensitivity

Excellent exon-level coverage with low dropout and high capture efficiency.

Low Input & FFPE Compatible

Optimized for challenging samples with as little as 50 ng input DNA.

Full Bioinformatics Pipeline

Includes SNV, InDel, CNV detection, and optional MSI/TMB analysis.

Sample Requirements

Note: Concentrations should be determined by fluorometry (Qubit, PicoGreen). If using spectrophotometry (e.g. NanoDrop), double the concentration values.

We accept a wide range of sample types and offer extraction services upon request.

Not sure if your sample qualifies? Contact us for free consultation and extraction support.

What You'll Receive

• Deliverables are tailored based on your project scope:
• Raw data files (FASTQ)
• Alignment files (BAM) and variation files (VCF)
• Statistical and annotation reports (PDF + Excel)
• Graphical analysis results
• Project documentation and usage guidance

Human/Mouse Whole Exome Seq FAQs

Q1: Why choose whole exome sequencing instead of whole genome sequencing?

A: Whole exome sequencing (WES) focuses on the ~1–2% of the genome that codes for proteins but captures ~85% of disease-causing mutations. It's a cost-effective solution when your research target involves gene-level functional variation.

Q2: What's the difference between your Human Exome and Mouse Exome Sequencing services?

A: Both services include probe-based capture of protein-coding regions (CDS), high-throughput sequencing, and variant interpretation. The Human Exome Panel is aligned to GRCh38 and includes ClinVar annotation, while the Mouse Exome Panel targets GRCm39 and supports disease model studies.

Q3: What depth of coverage do you recommend for human or mouse exome sequencing?

A: We recommend 100X–150X for germline studies and ≥200X for tumor/FFPE samples. For mouse whole exome sequencing, deeper coverage may be required for mosaic or chimeric models.

Q4: Do you support long-read exome sequencing using Nanopore or PacBio SMRT?

A: Yes. For select applications requiring structural variant detection or highly repetitive regions, we offer long-read exome capture using Nanopore or SMRT platforms. Please contact us for customized protocols.

Q5: How do you ensure variant accuracy in FFPE or low-input samples?

A: We use optimized library prep kits with UMI (unique molecular identifiers), FFPE-aware capture panels, and tailored bioinformatics pipelines to improve sensitivity and reduce artefacts.

Q6: Can I submit pre-enriched exome libraries for sequencing only?

A: Yes. We accept both raw genomic DNA and pre-captured libraries. Please contact us for library QC requirements.

Q7: What deliverables will I receive after analysis?

A: You'll receive raw data (FASTQ), aligned files (BAM), variant calls (VCF), annotated variant lists (Excel), and optional CNV or pathway reports.

Q8: How do I choose between whole exome and whole genome sequencing?

A: Choose whole genome sequencing if your study requires analysis of non-coding variants, structural variations, or intergenic regulatory elements. For gene-level mutation discovery, human whole exome sequencing offers higher depth at lower cost.

Human/Mouse Whole Exome Seq Case Studies

Customer Publication Highlight

Case Study: Integrated Exome & Optical Mapping in Clear Cell Renal Cell Carcinoma

Title: Optical genome and epigenome mapping of clear cell renal cell carcinoma
Journal: NAR Cancer
Published: March 4, 2025
DOI: 10.1093/narcan/zcaf008  

Background

Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, often driven by complex genomic events such as the loss of chromosome 3p and inactivation of the VHL gene. However, epigenetic factors—including DNA methylation and hydroxymethylation—also play critical roles in tumor progression. Capturing both types of variation in a single workflow is challenging with traditional sequencing methods.

Project Objectives

• Hybrid Characterization: Combine short-read exome sequencing with optical genome mapping to detect both coding mutations and large-scale structural variations (SVs).
• Epigenetic Profiling: Measure single-molecule methylation (5mC) and hydroxymethylation (5hmC) changes in tumor vs. normal tissue.
• Clinical Insight: Tie genetic and epigenetic alterations to functional gene changes for ccRCC pathogenesis.

CD Genomics' Services

1. Exome Sequencing

• Samples: Tumor and matched adjacent normal tissue
• Platform: Human Whole Exome Sequencing – Core Panel (Illumina PE150, ~100 × coverage)
• Analysis: GATK-based variant calling (SNV/InDel) with focused annotation of VHL, PBRM1, SETD2, and other epigenetic driver genes.

2. Optical Genome/Epigenome Mapping

(This component was conducted by the research team)

• Structural variant detection with single-molecule resolution
• Single-molecule methylation profiling using labelled DNA molecules

3. Integrated Analysis

• Cross-validation of exome-detected variants with copy number and structural findings from optical mapping
• Comparative epigenomic profiling of 5mC and 5hmC levels in key tumor suppressors

Key Findings

Co-occurring Genetic & Epigenetic Events

• Identification of a 3p deletion encompassing VHL and PBRM1 confirmed by optical mapping.
• Exome-sequencing detected non-synonymous mutations in SETD2 and BAP1 consistent across both tumor stages.

Epigenetic Dysregulation

• Global reduction of 5hmC in tumor compared to normal tissue.
• Hypo-/hypermethylation patterns in promoter/enhancer regions of VHL, PRCC, and PBRM1 correlated with reduced expression.

Functional Genomic Insights

• Combined data revealed disrupted metabolic and hypoxia pathways that contribute to ccRCC progression.

This panel shows the structural variant map of chromosome 3p (tumor vs control), clearly displaying the 3p deletion detected through optical genome mapping.

Implications

• Comprehensive Profiling: Combining exome sequencing with optical genome mapping enables complete coverage—from point mutations to large structural changes.
• Enhanced Clinical Insight: Epigenetic markers (5hmC/5mC) provide additional layers of tumor biology previously hidden to NGS-only approaches.
• Strategic Approach in Cancer Research: This dual-modality method effectively addresses why whole exome sequencing alone might miss critical alterations in cancers like ccRCC.

Why This Matters for You

This case underscores the power of integrating Human Exome Sequencing (for SNVs and InDels) with long-range structural and epigenetic mapping to fully unravel cancer genomes. At N2 Jenomics Lab Pvt. Ltd. , we can help you implement such integrative strategies—leveraging both exome panels and long-read platforms like Nanopore or PacBio, complemented by optical genome mapping partnerships.